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Abstract
Purpose The radiolanthanide 161Tb (T 1/2=6.90 days,
Eβ−av=154 keV) was recently proposed as a potential alterna-
tive to 177Lu (T1/2=6.71 days, Eβ
−
av=134 keV) due to similar
physical decay characteristics but additional conversion and
Auger electrons that may enhance the therapeutic efficacy. The
goal of this study was to compare 161Tb and 177Lu in vitro and
in vivo using a tumour-targeted DOTA-folate conjugate (cm09).
Methods 161Tb-cm09 and 177Lu-cm09 were tested in vitro on
folate receptor (FR)-positive KB and IGROV-1 cancer cells
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) viability assay. In vivo 161Tb-cm09 and
177Lu-cm09 (10 MBq, 0.5 nmol) were investigated in two
different tumour mouse models with regard to the bio-
distribution, the possibility for single photon emission computed
tomography (SPECT) imaging and the antitumour efficacy.
Potentially undesired side effects were monitored over 6 months
by determination of plasma parameters and examination of
kidney function with quantitative SPECT using 99mTc-
dimercaptosuccinic acid (DMSA).
Results To obtain half-maximal inhibition of tumour cell viabil-
ity a 4.5-fold (KB) and 1.7-fold (IGROV-1) lower radioactivity
concentration was required for 161Tb-cm09 (IC50 ~0.014 MBq/
ml and ~2.53 MBq/ml) compared to 177Lu-cm09 (IC50
~0.063MBq/ml and ~4.52MBq/ml). SPECTimaging visualized
tumours of mice with both radioconjugates. However, in therapy
studies 161Tb-cm09 reduced tumour growthmore efficiently than
177Lu-cm09. These findings were in line with the higher
absorbed tumour dose for 161Tb-cm09 (3.3 Gy/MBq) compared
to 177Lu-cm09 (2.4Gy/MBq). None of themonitored parameters
indicated signs of impaired kidney function over the whole time
period of investigation after injection of the radiofolates.
Conclusion Compared to 177Lu-cm09 we demonstrated equal
imaging features for 161Tb-cm09 but an increased therapeutic
efficacy for 161Tb-cm09 in both tumour cell lines in vitro and
in vivo. Further preclinical studies using other tumour-
targeting radioconjugates are clearly necessary to draw final
conclusions about the future clinical perspectives of 161Tb.
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Introduction
The concept of peptide receptor radionuclide therapy (PRRT)
using radiolabelled somatostatin analogues (e.g. DOTATATE
and DOTATOC) proved its potential for the management of
patients with inoperable or metastasized neuroendocrine tumours
over many years [1, 2]. The first particle-emitting radioisotope
used for PRRT was 90Y, which decays with a half-life of 2.67
days by emission of β−-particles of a relatively high energy
(Eβ−av=934 keV) [3]. In spite of the encouraging results
obtained with PRRT, it has occasionally resulted in severe neph-
rotoxicity [4, 5]. By introduction of the radiolanthanide 177Lu
(T1/2=6.71 days, Eβ
−
av=134 keV) as an alternative to
90Y [6, 7]
undesired side effects to the kidneys became less problematic due
to its softer β−-energy spectrum compared to 90Y [8].
Herein, we propose another radiolanthanide, 161Tb, as an
alternative isotope for targeted radionuclide therapy [9–11].
161Tb decays with a half-life of 6.90 days by emission of
low-energy β−-particles (Eβ−av=154 keV) [9]. Similar to
177Lu which emits gamma radiation of energies suitable for
single photon emission computed tomography (SPECT) imag-
ing, the β−-decay of 161Tb is accompanied by emission of
gamma rays of energies (Eγ=25.7 keV, 48.9 keV, 74.6 keV)
that allow its use for SPECTas well. Importantly, 161Tb emits a
significant number of conversion and Auger electrons of
energies ≤ 40 keV (~12.12 e−, ~36.1 keV per decay) compared
to 177Lu whose decay is accompanied by only a negligible
number of electrons (~1.11 e−, ~1.0 keV per decay) in the same
energywindow (Table 1) [12]. This additional energy release of
161Tb is even higher than for commonly employed Auger and
conversion electron emitters such as 125I (~23.95 e−, ~19.2 keV
per decay) and 123I (~13.71 e−, ~7.2 keV per decay) or 111In
(~7.43 e−, ~6.9 keV per decay) and 67Ga (~4.96 e−, ~6.6 keV
per decay) [12]. Since both 177Lu and 161Tb belong to the group
of lanthanides, the same (radio)chemistry may be applied and
hence the formation of highly stable complexes of 177Lu upon
coordination by a DOTA chelator is also possible for 161Tb [9].
Recently, we have implemented routine production of 161Tb [9]
at the Paul Scherrer Institute. The radiopharmaceutical utility of
this and other Tb radioisotopes has been demonstrated in a
recent proof-of-concept study [11].
The aim of this study was to compare 161Tb with 177Lu and
to evaluate potentially different features in terms of SPECT
imaging and in vitro and in vivo antitumour efficacy. For this
purpose we employed a recently developed DOTA-folate con-
jugate (cm09) which previously proved favourable in vitro and
in vivo properties [13]. Due to the improved tissue distribution
profile of 177Lu-cm09 compared to conventional folate
radioconjugates it could also be used for preclinical therapy
experiments with tumour-bearing mice [11, 13]. Therefore, the
folate conjugate (cm09) appeared to be an excellent tool to
investigate 161Tb and compare it with 177Lu (Fig. 1).
In vitro 161Tb-cm09 and 177Lu-cm09 were investigated
with regard to their effects on the viability of folate receptor
(FR)-positive cancer cells upon exposure to variable radio-
activity concentrations. In vivo therapy studies were performed
with 161Tb-cm09 and 177Lu-cm09 for direct comparison in
established tumour mouse models. For this purpose we used
KB (human cervical carcinoma) and IGROV-1 (human ovarian
carcinoma) tumour xenografts. The two radiolanthanides 161Tb
and 177Lu were also compared with regard to their potential for
preclinical SPECT imaging, whichwe investigated by phantom
studies and by in vivo scans in tumour-bearing mice.
Materials and methods
Radioisotopes
No-carrier-added (n.c.a.) 161Tb was produced by irradiation of
enriched 160Gd targets for 3 weeks at the spallation-induced
neutron source (SINQ) at PSI (Villigen-PSI, Switzerland) or
by irradiation for 1 week at the high-flux nuclear reactor of
ILL (Grenoble, France) [11]. Isolation and formulation of high
concentrated 161TbCl3 in 0.05 M HCl (2–3 GBq/100 μl) was
performed according to the procedure previously reported
by Lehenberger et al. [9]. 177LuCl3 (in 0.04 M HCl) was
obtained from Isotope Technologies Garching GmbH (ITG
GmbH, Munich, Germany) at an activity concentration of
1 GBq/100 μl. The exact amount of radioactivity of these
radionuclides was measured with a calibrated N-type high-
purity germanium (HPGe) coaxial detector (EURISYS
MESURES) and the Ortec InterWinner 5.0 software.
Radiofolate synthesis
Depending on the activity concentration of the radioisotopes,
x μl of a 161TbCl3 or
177LuCl3 solution corresponding to
Table 1 Comparison of the production and decay properties of 161Tb and
177Lu
Isotope 161Tb 177Lu
Production 160Gd(n,γ)161Gd→
161Tb [9]
(1) 176Lu(n,γ)177Lu [23, 24]
(2) 176Yb(n,γ)177Yb→177Lu [25]
Half-life 6.90 days 6.71 days
Eβ
−
av (intensity) 154 keV (1.00) 134 keV (1.00)
Eγ (intensity) 25.7 keV (0.23) 112.9 keV (0.062)
48.9 keV (0.17) 208.4 keV (0.104)
74.6 keV (0.10)
Conversion and
Auger electrons
(intensity) [12]
0–0.1 keV (0.72) 0–0.1 keV (0.27)
0.1–1 keV (7.38) 0.1–1 keV (0.55)
1–10 keV (3.03) 1–10 keV (0.30)
10–20 keV (0.42) 10–20 keV
20–30 keV (0.18) 20–30 keV
30–40 keV (0.39) 30–40 keV
0–40 keV (12.13) 0–40 keV (1.11)
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300 MBq was added to a mixture of cm09 (10 μl, 10−3 M),
0.05 M HCl (100-x μl) and 0.5 M sodium acetate (20 μl) to
obtain 161Tb-cm09 and 177Lu-cm09 at a specific activity of up
to 30 MBq/nmol. The reaction solution was heated for 10 min
at 95 °C. After cooling down to room temperature Na-
diethylenetriaminepentaacetic acid (Na-DTPA, 10 μl, 5 mM,
pH 5) was added for complexation of potential traces of
unreacted 161Tb(III) and 177Lu(III), respectively. Quality
control was performed by HPLC using a C18 reversed phase
column (XTerraMSC18, 5 μm, 15 cm × 4.6 cm,Waters). The
mobile phase consisted of Milli-Q water with 0.1 %
trifluoroacetic acid (A) and methanol (B) with a linear
gradient from 5 % B to 80 % B over 25 min at a flow rate
of 1 ml/min.
Cell culture
KB cells (human cervical carcinoma cell line, HeLa subclone;
ACC-136) were purchased from the German Collection of
Microorganisms and Cell Cultures (DSMZ, Braunschweig,
Germany). IGROV-1 cells (human ovarian carcinoma cell line)
were a kind gift from Dr. Gerrit Jansen (Department of Rheu-
matology, VU University Medical Center, Amsterdam, The
Netherlands). The cells were cultured as monolayers at 37 °C
in a humidified atmosphere containing 5%CO2. Both cell lines
were grown in folate-free cell culture medium, FFRPMI
(modified RPMI, without folic acid, vitamin B12 and phenol
red, Cell Culture Technologies GmbH, Gravesano/Lugano,
Switzerland) supplemented with 10 % heat-inactivated fetal
calf serum (FCS, as the only source of folate), L-glutamine
and antibiotics (penicillin/streptomycin/fungizone).
In vitro experiments were performed with 161Tb and 177Lu
in salt form (161TbCl3 and
177LuCl3), with DTPA-coordinated
radioisotopes (161Tb-DTPA and 177Lu-DTPA) and with the
radiolabelled folate conjugates (161Tb-cm09 and 177Lu-cm09)
at the same specific activity (20 MBq/nmol) which was
employed for in vivo experiments.
In vitro cell viability assay
Cell viability was assessed using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as
described by Mosmann [14]. KB cells and IGROV-1 cells
(2,500 cells in 200 μl FFRPMI with supplements) were
seeded in 96-well plates. After incubation overnight to allow
adhesion of the cells, the supernatants were removed and the
cells were incubated in 200 μl FFRPMI medium (without
supplements) containing 161Tb-cm09 and 177Lu-cm09,
respectively (0.0001–10 MBq/ml). Control assays were
performed with cells incubated with FFRPMI medium with-
out radioactivity. After 4 h incubation at 37 °C, cells were
washed once with 200 μl phosphate-buffered saline (PBS)
followed by addition of 200 μl of FFRPMI medium (with
supplements) to each well. Cells were grown over 4 days
under standard cell culture conditions (37 °C, 5 % CO2 and
high humidity), before addition of MTT reagent (5 mg/ml in
PBS, 30 μl per well). The well plates were incubated for an
additional 4 h allowing the formation of dark-violet formazan
crystals. Upon replacement of the FFRPMI medium by
dimethyl sulphoxide (DMSO, 200 μl per well) to dissolve
the crystals, determination of the absorbance was carried out
at 560 nm using a microplate reader (VICTOR X3,
PerkinElmer). To quantify cell viability, the absorbance of
the test samples was expressed as percentage of the absor-
bance of control cell samples which was set to 100 %.
Sigmoid inhibition curves were determined and the radio-
activity concentration (MBq/ml) which reduced cell viability
to 50 % of untreated control cells was indicated as half-
maximal inhibitory concentration (IC50) using GraphPad
Prism (version 5).
In vivo studies
In vivo experiments were approved by the local veterinarian
department and conducted in accordance with the Swiss law
on animal protection. Four- to five-week-old female, athymic
Fig. 1 Chemical structure of the
folate radioconjugate (M-cm09)
comprising folic acid as the FR-
targeting ligand, an albumin-
binding entity to enhance the
blood circulation time and a
DOTA chelator for stable
coordination of the radioisotope
(M=161Tb, 177Lu)
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nude mice (CD-1 Foxn1/nu) were purchased from Charles
River Laboratories (Sulzfeld, Germany). The animals were
fed with a folate-deficient rodent diet (Harlan Laboratories)
starting 5 days prior to tumour cell inoculation [15].
SPECT/CT imaging studies
SPECT/CT experiments were performed with a four-head
multiplexing multi-pinhole camera (NanoSPECT/CT,
Bioscan, Inc., Washington, DC, USA) using collimators of
4×9 holes with a diameter of 1.4 mm. The scans were ac-
quired using Nucline software (version 1.02, Bioscan, Inc.).
Mice were inoculated with KB cells (5×106 cells in 100 μl
PBS) into the subcutis of each shoulder. Imaging studies were
performed about 14 days after KB tumour cell inoculation.
SPECT/CT scans were performed the day after intravenous
injection of 161Tb-cm09 (~30 MBq, 1 nmol) and 177Lu-cm09
(~30 MBq, 1 nmol) with a time per view of 35 s resulting in a
scan time of about 20–30 min. CT scans were performed with
the integrated CT using a tube voltage of 55 kVp and an
exposure time of 1,000 ms per view. After acquisition, SPECT
data were reconstructed iteratively with HiSPECT software
(version 1.4.3049, Scivis GmbH) using gamma energies of
47.7 keV (± 10 %) and 74.6 keV (± 10 %) for 161Tb and
gamma energies of 56.1 keV (± 10 %), 112.9 keV (± 10 %)
and 208.4 keV (± 10 %) for 177Lu. For each gamma line the
energy peak had a full width of 20 %. The real-time CT
reconstruction used a cone-beam filtered backprojection.
SPECT and CT data were automatically coregistered as both
modalities share the same axis of rotation. The fused data sets
were analysed with the InVivoScope post-processing software
(version 2.0, Bioscan, Inc.).
Blood clearance
Two groups of three non-tumour-bearing nude mice were
intravenously injected with either 161Tb-cm09 (20 MBq,
1 nmol) or 177Lu-cm09 (20 MBq, 1 nmol). At different time
points after injection (5 min, 15 min, 30 min, 1 h, 2 h, 6 h, 20 h,
48 h and 72 h) blood was taken from the tail vein or sublingual
vein (3–40 μl) and measured in a gamma counter. The mea-
sured radioactivity per millilitre blood was calculated and
converted into the percentage of the value measured at the first
time point [5 min post-injection (p.i.)] which was set to 100 %.
Biodistribution studies
For post-mortem biodistribution studies mice were inoculated
with IGROV-1 cells (6.5×106 cells in 100 μl PBS) into the
subcutis of each shoulder. The experiments were performed in
triplicate approximately 16 days after tumour cell inoculation.
The radioconjugates were diluted with PBS to the desired
specific activity (2–3 MBq, 0.5 nmol per mouse) for
immediate administration via a lateral tail vein. The animals
were sacrificed at specified time points between 1 h p.i. and
168 h p.i. and tissues and organs were collected, weighed
and counted for radioactivity in a gamma counter. The results
were listed as the percentage of the injected dose per gram of
tissue weight (%ID/g), using reference counts from a defined
volume of the original injectate that was counted at the same
time.
To estimate the equivalent absorbed radiation dose for 161Tb-
cm09 and 177Lu-cm09 in tumour xenografts and in the kidneys,
the following assumptions were made. First, the biodistribution
data were considered as equal for 161Tb-cm09 and 177Lu-cm09
and second, the uptake in KB and IGROV-1 tumour xenografts
was considered as the same (Supplementary Material).
In vivo therapy studies
Mice were inoculated with KB cells (4.5×106 cells in 100 μl
PBS) or IGROV-1 cells (7×106 cells in 100 μl PBS) under the
skin of each shoulder 4 days before the start of therapy at day 0.
Micewereweighed 3–4 times aweek over a time period of about
7 weeks. Tumour volume was determined every other day using
a digital caliper and calculated according to the equation
[0.5×(L×W2)] where L is the measurement of the longest axis
and W is the measurement of the axis perpendicular to L in
millimetres [16]. The relative tumour volume (RTV)was defined
as [Vx/V0] where Vx is the volume in cubicmillimetres at a given
time x and V0 at day 0. The efficacy of the folate radioconjugate
application was expressed as the percentage tumour growth
inhibition (% TGI), calculated using the equation [100 − (T/C
× 100)], where T is themeanRTVof the treatedmice andC is the
mean RTV in the control group at the time of euthanasia of the
first mouse of the control group [17]. Tumour growth delay
(TGDx) was calculated as the time required for the tumour
volume to increase x-fold over the initial volume at day 0.
Tumour growth delay index (TGDIx) was calculated as the
TGDx ratio of treated over control mice [TGDIx=TGDx(T)/
TGDx(C)]. For the present studies we calculated the TGD as
the time required to observe a fivefold (TGD5) and tenfold
(TGD10) increase of the initial tumour volume allowing the
determination of TGDI5 and TGDI10.
Endpoint criteria were defined as body weight loss of >15 %
of the initial body weight (at day 0), tumour volume
>1,500 mm3 (KB xenografts) or >1,000 mm3 (IGROV-1
xenografts), ulceration or bleeding of the tumour xenograft or
abnormal behaviour indicating pain or unease of the animal.
Mice were removed from the study and euthanized upon
reaching one of the predefined endpoint criteria. To calculate
significance of the survival time or TGD, a t test (Microsoft
Excel software) was used. All analyses were two-tailed and
considered as type 3 (two sample unequal variance). A
p value<0.05 was considered statistically significant.
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Model 1: 161Tb-cm09 and 177Lu-cm09 therapy in KB tumour-
bearing mice Three groups of six mice (group A) or eight
mice (groups B and C) were injected with only PBS (group A,
control) or with 161Tb-cm09 (group B, 10 MBq, 0.5 nmol) or
177Lu-cm09 (group C, 10 MBq, 0.5 nmol) at day 0 when the
average KB tumour volume reached 54±14 mm3 (group A),
57±17 mm3 (group B) and 58±16 mm3 (group C).
Model 2: 161Tb-cm09 and 177Lu-cm09 therapy in IGROV-1
tumour-bearing mice Three groups of six mice (group A) or
eight mice (groups B and C) were injected with only PBS
(group A, control) or with 161Tb-cm09 (group B, 10 MBq,
0.5 nmol) or 177Lu-cm09 (group C, 10 MBq, 0.5 nmol) at day
0 when the average IGROV-1 tumour volume reached 35±
8 mm3 (group A), 39±13 mm3 (group B) and 40±12 mm3
(group C).
Comparison of side effects after therapy with 161Tb-cm09 and
177Lu-cm09 In a separate experiment three groups (A–C) of
non-tumour-bearing nude mice were intravenously injected
with either only PBS (group A, n =3), with 20 MBq 161Tb-
cm09 (group B, n =6) or 177Lu-cm09 (group C, n =3) at day 0.
Mice were weighed 3–4 times a week over a time period of
6 months. Plasma parameters including alkaline phosphatase
(ALP) and blood urea nitrogen (BUN) weremeasured from all
mice at days 29, 69, 127 and 147 after the start of therapy.
Plasma samples were prepared by centrifugation of blood
samples (150–200 μl per mouse) drawn from the sublingual
vein of each mouse and collected in heparinized vials
(Microvette, 200 ml, Sarstedt, Nümbrecht, Germany). For
each parameter a plasma volume of 10 μl was required for
measurement using a Fuji Dri-Chem 40000i analyser
(Polymed Medical Center AG, Glattbrugg, Switzerland).
Results
Radiosynthesis of 161Tb-cm09 and 177Lu-cm09
Radiolabelling of the folate conjugate (cm09) with 161Tb or
177Lu was performed under equal conditions in a solution of
sodium acetate and hydrochloric acid at pH 4.5. The
radiolabelling was accomplished within 10 min incubation at
95 °C. HPLC-based quality control revealed equal retention
times (Rt=19.45 min) for
161Tb-cm09 and 177Lu-cm09. The
radiochemical yield of 161Tb-cm09 and 177Lu-cm09 was
always >98 % at a specific activity of up to 30 MBq/nmol.
Cell experiments
The viability of KB and IGROV-1 cancer cells was
investigated by MTT assays upon exposure of these cells to
increasing radioactivity concentrations of 161Tb-cm09 and
177Lu-cm09. Determination of the IC50 values—which
represent the radioactivity concentration needed to reduce cell
viability to 50 % of untreated controls—using KB cells
revealed a concentration of 0.014±0.013 MBq/ml for 161Tb-
cm09 and 0.063±0.021 MBq/ml for 177Lu-cm09 (Fig. 2a).
For IGROV-1 cells an IC50 value of 2.53±0.47 MBq/ml was
obtained for 161Tb-cm09 and 4.52±0.98 MBq/ml for 177Lu-
cm09 (Fig. 2b).
In vivo SPECT/CT imaging studies
In vivo SPECT/CTstudies were performed 24 h after injection of
161Tb-cm09 and 177Lu-cm09 in tumour-bearing mice (Fig. 3).
High accumulation of radioactivity was found in KB tumour
xenografts located on each shoulder and in the kidneys which
express the FR in the proximal tubules. Imaging quality was
Fig. 2 a Inhibitory effects of increasing radioactivity concentrations of
161Tb-cm09 (IC50 0.014±0.013 MBq/ml) and
177Lu-cm09 (IC50 0.063±
0.021 MBq/ml) in KB cells. b Inhibitory effects of increasing radio-
activity concentrations of 161Tb-cm09 (IC50 2.53±0.47 MBq/ml) and
177Lu-cm09 (IC50 4.52±0.98 MBq/ml) in IGROV-1 cells
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excellent in the case of a mouse injected with 161Tb-cm09
(Fig. 3a) and comparable to the quality obtained with a mouse
which received 177Lu-cm09 (Fig. 3b).
Blood clearance
The results of the studywhichwas performed to determine blood
clearance values clearly showed equal clearance curves for
161Tb-cm09 and 177Lu-cm09 over the whole time of investiga-
tion (Fig. 4). The average values for 161Tb-cm09 and 177Lu-
cm09 did not differ significantly (p<0.05). The biological half-
life of the radioactive conjugates 161Tb-cm09 and 177Lu-cm09
was about 70 min.
Biodistribution studies
Biodistribution data of 161Tb-cm09 and 177Lu-cm09 in KB
tumour-bearing mice have recently been reported by our
group [11, 13]. Herein, additional tissue distribution data were
obtained in IGROV-1 tumour-bearing mice after injection of
161Tb-cm09 (Supplementary Material, Table S1). The uptake
of 161Tb-cm09 in IGROV-1 tumour xenografts was about
13 %ID/g at 1 h p.i. and 23 %ID/g at 4 and 24 h p.i. Over
time, accumulation of radioactivity in the tumour tissue de-
creased to about 6 %ID/g at 7 day p.i. These findings were
equal to those obtained for KB tumour xenografts over the
whole time of investigation (Fig. 5, Supplementary Material,
Table S2 [11]).
Biological effectiveness of 161Tb-cm09 and 177Lu-cm09
The absorbed fractions for the assumed spherical size
of the tumours ranged between 0.90 and 0.95. The cal-
culated absorbed dose of 3.3 Gy/MBq for 161Tb-cm09
and 2.4 Gy/MBq for 177Lu-cm09 in KB and IGROV-1
tumours resulted in an absorbed dose of ~33 Gy and
~24 Gy after injection of 10 MBq 161Tb-cm09 and
177Lu-cm09, respectively. For the kidneys, an absorbed
dose of 4.5 Gy/MBq was estimated for 161Tb-cm09 and
3.4 Gy/MBq for 177Lu-cm09. In an additional study non-
tumour-bearing mice received 20 MBq 161Tb-cm09 and
20 MBq 177Lu-cm09 resulting in a kidney dose of ~90 Gy
for 161Tb-cm09 and ~68 Gy for 177Lu-cm09.
Fig. 3 In vivo SPECT/CT images acquired with dedicated small animal
SPECT/CTscanner (NanoSPECT/CT™, Bioscan, Inc., Washington, DC,
USA). KB tumour-bearing mice were scanned for 20–30 min 24 h after
injection of ~30 MBq 161Tb-cm09 (a) and after injection of ~30 MBq
177Lu-cm09 (b), respectively. Tumour xenografts and kidneys are indi-
cated with white and yellow arrows
Fig. 4 Blood clearance values for
161Tb-cm09 (green) and 177Lu-
cm09 (red) shown as the blood
activity in % of the initially
measured radioactivity (5 min p.i.
of the radioconjugates) in the
blood which was set to 100 %
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Therapy studies
The time course of tumour growth in control mice with KB
tumours (model 1) was slightly different than in mice bearing
IGROV-1 tumours (model 2). While the size of all KB tumours
increased uniformly over time, more variability in tumour size
and faster tumour growth was observed for IGROV-1 tumour
xenografts (Fig. 6a, b). The first control mouse ofmodel 1 had to
be euthanized at day 26, whereas in model 2 the first control
mouse was euthanized already at day 16, both because of
oversized tumours. A clearly reduced tumour growth was found
in both groups of mice which received radionuclide therapy,
independent of the radioconjugate (161Tb-cm09 versus 177Lu-
cm09) and the tumour mouse model (KB versus IGROV-1)
(Fig. 6a, b). Consistent in both tumour mouse models was a
more pronounced antitumour effect in mice which received
161Tb-cm09 (group B) than in mice which received 177Lu-
cm09 (group C). This observation was quantified by calculation
of the TGI. In model 1 the TGI was 72 % for mice which
received 161Tb-cm09. This value was significantly (p<0.005)
higher than the TGI of 46 % which was observed in mice
treated with 177Lu-cm09. Also, in model 2 the TGI of 90% for
the mice which received 161Tb-cm09 was significantly
(p <0.05) increased compared to the TGI of 83 % obtained
in animals treated with 177Lu-cm09 (Table 2). The TGD
indices TGDI5 and TGDI10 were increased for mice treated
with 161Tb-cm09 compared to mice treated with 177Lu-cm09
in both models (1 and 2, Table 2).
The average survival time in KB tumour-bearing mice
(model 1) was 31 days for control mice (group A), 54 days
Fig. 5 Accumulation (%ID/g) of 161Tb-cm09 in IGROV-1 and KB
tumour xenografts over a time period of 7 days
Fig. 6 Tumour growth curves indicated as the relative tumour volumes
(RTV) of KB tumour-bearing mice (a) and IGROV-1 tumour-bearing
mice (b). Survival curves of KB tumour-bearing mice (c) and IGROV-1
tumour-bearing mice (d). Control mice (group A) are shown in blue,
mice treated with 161Tb-cm09 (group B) are shown in green and mice
treated with 177Lu-cm09 (group C) are shown in red
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for mice treated with 161Tb-cm09 (group B) and 35 days for
mice treated with 177Lu-cm09 (group C). In mice with
IGROV-1 tumour xenografts (model 2) the average survival
time was 19 days for control mice (group A), 31 days for mice
treated with 161Tb-cm09 (group B) and 30 days for mice
treated with 177Lu-cm09 (group C) (Fig. 6c, d, Table 2).
Comparison of side-effects after therapy with 161Tb-cm09
and 177Lu-cm09
The average value for the two plasma parameters ALP and
BUN was in the same range for mice treated with 161Tb-cm09
and 177Lu-cm09 (groups A and B) and control mice (Table 3).
Only at day 127 did mice treated with 177Lu-cm09 show an
increased value of the ALP level relative to control mice of
group A. However, at day 174 the values of the two groups of
animals were again in the same range.
During the whole time of investigation plasma parameters
such as aspartate aminotransferase, alanine aminotransferase,
total bilirubin and albumin of treated mice did not differ
significantly from those of control mice (Supplementary
Material, Table S3). Moreover, the amount of viable, apopto-
tic and dead white blood cells were not significantly different
among the two groups (B and C) of treated mice and among
treated mice and untreated controls (Supplementary Material,
Table S4). Investigations of renal uptake of 99mTc-
dimercaptosuccinic acid (DMSA) using quantitative SPECT
also did not reveal impairment of kidney function in animals
which were treated with 161Tb-cm09 and 177Lu-cm09 (Sup-
plementary Material).
Discussion
In this study 161Tb and 177Lu were compared in vitro and
in vivo. Radiolabelling of the DOTA-folate conjugate cm09
was accessible at high specific activity with both
radiolanthanides. SPECT phantom studies of 161Tb and
177Lu revealed an excellent imaging quality and a resolution
which was comparable for both radionuclides (Supplementary
Material, Fig. S1). The quality of the mouse images obtained
from in vivo SPECT/CTstudies confirmed equal suitability of
161Tb and 177Lu for preclinical imaging purposes. The low-
energy gamma rays of 161Tb may be advantageous in view of
a clinical application as they result in reduced radiation expo-
sure of non-targeted tissue (e.g. bone marrow) [9, 18]. On the
other hand low-energy gamma rays of 161Tb may not be
equally appropriate for imaging purposes in patients because
of less efficient penetration through the tissue compared to the
higher gamma energies of 177Lu (Table 1).
Time-dependent cell uptake and internalization studies
confirmed equal in vitro characteristics of 161Tb-cm09 and
177Lu-cm09. In both cell lines we observed largely the same
uptake, but in KB cells internalization appeared to be some-
what faster than in IGROV-1 cells (Supplementary Material
Fig. S2). In KB and IGROV-1 cells, application of non-
internalizing 161Tb and 177Lu (applied as 161Tb- and 177Lu-
DTPA complexes) resulted in equal reduction of cell viability
(Supplementary Material Fig. S3). However, application of
unspecific internalizing 161Tb and 177Lu (applied as 161TbCl3
and 177LuCl3) resulted consistently in an increased efficacy of
161Tb than of 177Lu (Supplementary Material Fig. S4). As
Table 2 Results of the therapy studies using 161Tb-cm09 and 177Lu-cm09 in model 1 and model 2
Model 1: KB tumour-bearing mice
Group Mouse ID Test agent MBq TGDI5 TGDI10 TGI Additional survival time
A A1–A6 PBS − 1.00 1.00 − −
B B1–B8 161Tb-cm09 10 2.17 1.80 72 % + 74 %
C C1–C8 177Lu-cm09 10 1.67 1.30 46 % + 13 %
Model 2: IGROV-1 tumour-bearing mice
Group Mouse ID Test agent MBq TGDI5 TGDI10 TGI Survival time
A A1–A6 PBS − 1.00 1.00 − −
B B1–B8 161Tb-cm09 10 2.75 2.67 90 % + 63 %
C C1–C8 177Lu-cm09 10 2.50 2.00 83 % + 58 %
Table 3 List of plasma values of mice of group A (n=3), group B (n =6)
and group C (n =3)
Group Day 29 Day 69 Day 127 Day 174
ALP (U/L)
A (control) 81±33 51±23 36±10 33±18
B (161Tb-cm09) 57±10 46±14 48±25 49±25
C (177Lu-cm09) 84±8 58±20 64±8* 62±23
BUN (mmol/L)
A (control) 6.23±0.61 7.27±1.16 6.46±0.29 4.74±0.25
B (161Tb-cm09) 6.21±0.61 7.32±1.11 6.03±1.31 6.68±2.88
C (177Lu-cm09) 6.23±1.59 6.23±0.21 7.53±0.55 7.49±2.30
ALP alkaline phosphatase, BUN blood urea nitrogen
*Significance compared to controls (p<0.05)
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expected, application of 161Tb-cm09 and 177Lu-cm09 showed
an FR-specific inhibitory effect on tumour cell viability
in vitro. The inhibitory effect was more pronounced in the
case of incubating cells with 161Tb-cm09 than with 177Lu-
cm09 and in both cases the effect was clearly better than what
was observed with an unspecific treatment (Supplementary
Material Fig. S5). In KB cells a 4.5-fold lower radioactivity
concentration was required for 161Tb-cm09 to reduce cell
viability to 50 % of untreated controls than for 177Lu-cm09.
In the case of IGROV-1 cells a 1.8-fold lower radioactivity
concentration was required for 161Tb-cm09 to achieve the
same effect as with 177Lu-cm09. These in vitro findings were
in line with the increased absorbed dose provided by 161Tb
(β−-particles, conversion and Auger electrons) compared to
177Lu, if applied at the same radioactivity amount [9, 18].
The in vivo blood clearance curves of 161Tb-cm09 and
177Lu-cm09 demonstrated equal pharmacokinetic properties
of these radioconjugates independent of whether they were
radiolabelled with 161Tb or 177Lu. Also, both radioconjugates
were shown to be stable in vivo, while formation of radio-
active metabolites was not observed over at least 2 days after
injection (SupplementaryMaterial Fig. S6). The in vivo tissue
distribution profile of 161Tb-cm09 and 177Lu-cm09 was equal
in both tumour mouse models under standardized experimen-
tal conditions. The in vivo studies performedwith 161Tb-cm09
revealed an almost equally high uptake (~ 25%ID/g, 24 h p.i.)
in IGROV-1 and KB tumour xenografts (Supplementary
Material, Tables S1/S2). Comparison of the in vivo therapy
studies in KB and IGROV-1 tumour mouse models showed
that the tumour growth was more delayed after application of
161Tb-cm09 than after application of 177Lu-cm09. These find-
ings can be attributed to the fact that the absorbed dose in the
tumour tissue was higher for 161Tb-cm09 (3.3 Gy/MBq) than
for 177Lu-cm09 (2.4 Gy/MBq). IGROV-1 tumours grew faster
than KB tumours but were more sensitive to radionuclide
therapy as shown by the tumour growth curves in Fig. 6a, b.
However, the difference of the inhibitory effects of 161Tb-
cm09 and 177Lu-cm09 on the tumour growth was more pro-
nounced in KB tumours than in IGROV-1 tumours. The
reason for this observation is not clear. Since the therapeutic
efficacy of conversion and Auger electrons is clearly depen-
dent on the accumulation of the radionuclide in the tumour
cell [18–21], it is particularly the internalized fraction of
the radioconjugate which would be crucial to benefit from
the additional conversion and Auger electrons emitted by
161Tb. Only marginal differences were observed among KB
and IGROV-1 cells in terms of the internalized fraction of
the radioconjugates in vitro (Supplementary Material,
Fig. S2). However, it could be that KB cells internalize the
radioconjugates more efficiently in vivo which would explain
why the difference among 161Tb-cm09 and 177Lu-cm09 in
terms of TGD was greater in KB tumours than in IGROV-1
tumours.
The absorbed dose to the kidneys after application of
161Tb-cm09 (4.5 Gy/MBq) or 177Lu-cm09 (3.4 Gy/MBq)
was relatively high. Hence, there was a potential risk of
radio-nephrotoxicity. Therefore, an additional in vivo study
was performed in which non-tumour-bearing mice received
20 MBq of 161Tb-cm09 and 177Lu-cm09, respectively. This
high quantity of radioactivity was chosen because it was
known to result in complete tumour regression [13]. Signifi-
cant alterations of blood plasma parameters were not observed
over the whole time period of 6 months. Moreover, SPECT
experiments to quantify renal uptake of 99mTc-DMSA were
performed as a measure of kidney function. This method was
previously reported by Forrer et al. who investigated kidney
damage in rats after PRRT using 177Lu-DOTATATE [22]. Our
study revealed similar data for treated animals and untreated
control animals independent of whether they received 161Tb-
cm09 or 177Lu-cm09 (Supplementary Material Fig. S7,
Fig. S8 and Fig. S9). With regard to undesired effects to the
kidneys, further studies with a larger cohort of animals per
group and variable amounts of injected radioactivity are cur-
rently ongoing in our laboratories.
Conclusion
Based on the in vivo studies presented in this work it can be
concluded that 161Tb-cm09 provides an enhanced antitumour
effect compared to 177Lu-cm09 in KB and IGROV-1 tumour-
bearing mice. Radiotoxic side effects were not observed for
161Tb-cm09 and also not for 177Lu-cm09 even at high quan-
tities of injected radioactivity. These data indicate that 161Tb
could be a potent alternative to 177Lu for targeted tumour
therapy. Further preclinical studies using other tumour-
targeting ligands labelled with 161Tb and more detailed inves-
tigations about potential radiotoxic side effects are clearly
necessary to draw final conclusions about the future clinical
perspectives of 161Tb.
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